Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential|
|Author:||Tapia Rico, G.|
|Citation:||Expert Opinion on Biological Therapy, 2018; 18(4):449-457|
|Publisher:||Taylor & Francis|
|Gonzalo Tapia Rico and Timothy J. Price|
|Abstract:||Introduction: Atezolizumab is a fully humanized, engineered monoclonal antibody that specifically targets PD-L1, key molecule in the cancer-immunity pathway. Atezolizumab is currently approved for the treatment of metastatic non-small-cell lung cancer and advanced urothelial carcinomas. Areas covered: In this review, we will present the available data supporting the efficacy of atezolizumab for the treatment of metastatic colorectal cancer (mCRC). We will also provide an update on the ongoing/future clinical trials evaluating the role of atezolizumab for the treatment of CRC in different settings (alone or in combination with other checkpoint inhibitors and/or targeted therapies). So far, a small subgroup of mCRC (those with deficiency in mismatch repair - dMMR) appears to benefit significantly from checkpoint inhibitors. As expected, further research is needed to develop biomarkers, effective therapeutic strategies and novel combinations to overcome immune escape resistance and achieve better responses with minimal toxicities. Expert opinion: Interim analyses from ongoing early-phase studies in mCRC have shown encouraging activity of atezolizumab in combination with chemotherapy and/or targeted therapies, especially with MEK inhibitor cobimetinib. Within the next few years, this PD-L1 checkpoint inhibitor will likely be included as one of the treatment options for CRC, at least for patients with dMMR|
|Rights:||© 2018 Informa UK Limited, trading as Taylor & Francis Group|
|Appears in Collections:||Aurora harvest 3|
Mechanical Engineering publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.